---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-001663"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2025-01-07T23:59:59+00:00"
generated_at: "2026-05-28T09:11:07.711566+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# CERo Therapeutics reports cash balance of ~$5.5M as of Jan 7, 2025 after warrant exercises and equity line sales

## Summary
- Cash balance of approximately $5.463 million as of January 7, 2025.
- Funds raised through warrant exercises for Series A Preferred Stock and sales under committed equity financing facility.
- Filing updates prior 8-K on Dec 31, 2024; no other material changes.

## SEC filing metadata
- accession: 0001213900-25-001663
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2025-01-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390025001663/0001213900-25-001663-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390025001663/ea0227074-8k_cerotherap.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-001663
- JSON: https://secwatch.observer/filing/0001213900-25-001663.json
- Plain text: https://secwatch.observer/filing/0001213900-25-001663.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.